Underscoring concerns about ongoing drug shortages, two different ventures representing hundreds of hospitals across the U.S. are announcing separate deals on Wednesday in which manufacturers have agreed to provide medicines that are in short supply.

In the first deal, CivicaRx, which is a generic drug company formed by several large hospital systems and three philanthropies, has reached an agreement for Xellia Pharmaceuticals to manufacture antibiotics, including vancomycin and daptomycin. The deal marks the first such arrangement since CivicaRx launched several months ago. About 900 hospitals are part of the CivicaRx network.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy